Biometry

MyBiometry operates in the healthcare sector, focusing on asthma management through biomarker-driven insights. The company targets patients with asthma, providing them with actionable insights to lower their risk of attacks and improve asthma control. Utilizing patented sensors and devices, MyBiometry measures airway inflammation in breath via fractional exhaled nitric oxide (FeNO). This data is used to determine the risk of attacks, medication adherence, and exposure to environmental triggers. The business model revolves around delivering guideline-based coaching and education through a scalable app, recognized by the CDC for improving control and reducing costs. The app aggregates clinical and environmental risk factors to build personalized, predictive risk models for each patient. Revenue is generated through the provision of these services, which are scalable to millions of patients. The company leverages its own data to proactively engage patients before symptoms occur, aiming to improve self-management and reduce healthcare costs.

Keywords: asthma, biomarker, FeNO, sensors, risk assessment, self-management, healthcare, patients, app, coaching